{"filing":{"accession_number":"0001279569-26-000670","cik":"0001702123","ticker":"CRDL","company_name":"Cardiol Therapeutics Inc.","form":"6-K","filing_date":"2026-07-14","report_date":null,"primary_document":"cardiol6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1702123/000127956926000670/cardiol6k.htm"},"events":[{"id":17740,"run_id":15905,"accession_number":"0001279569-26-000670","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This news release announces the peer-reviewed publication of Phase II clinical trial data for CardiolRx™ in the Journal of the American Heart Association, with the pivotal Phase III MAVERIC trial nearing completion. The publication of positive Phase II results in a peer-reviewed journal is a material operational/clinical milestone for a late-stage biopharmaceutical company, as it strengthens the scientific foundation for the ongoing Phase III pivotal trial and demonstrates clinical efficacy and safety. This is a discrete clinical/operational event distinct from periodic financial reporting.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-07-14","form":"6-K","submitted_at":null,"items":[{"id":16328,"accession_number":"0001279569-26-000670","item_number":"EX-99.1","item_title":"ex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This news release announces the peer-reviewed publication of Phase II clinical trial data for CardiolRx™ in the Journal of the American Heart Association, with the pivotal Phase III MAVERIC trial nearing completion. The publication of positive Phase II results in a peer-reviewed journal is a material operational/clinical milestone for a late-stage biopharmaceutical company, as it strengthens the scientific foundation for the ongoing Phase III pivotal trial and demonstrates clinical efficacy and safety. This is a discrete clinical/operational event distinct from periodic financial reporting.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:38:37.646849+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16328,"accession_number":"0001279569-26-000670","item_number":"EX-99.1","item_title":"ex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This news release announces the peer-reviewed publication of Phase II clinical trial data for CardiolRx™ in the Journal of the American Heart Association, with the pivotal Phase III MAVERIC trial nearing completion. The publication of positive Phase II results in a peer-reviewed journal is a material operational/clinical milestone for a late-stage biopharmaceutical company, as it strengthens the scientific foundation for the ongoing Phase III pivotal trial and demonstrates clinical efficacy and safety. This is a discrete clinical/operational event distinct from periodic financial reporting.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:38:37.646849+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-07-14"}]}